Soft rush

Soft Rush (Juncus effusus L.): A Comprehensive Reference Article

1. Identity and Botanical Overview

Taxonomy and Nomenclature

Soft rush, known scientifically as Juncus effusus L., is a perennial herbaceous flowering plant species in the family Juncaceae. Its most widely used common names include soft rush, common rush, and lamp rush. In Traditional Chinese Medicine (TCM), the stem pith is known as Deng Xin Cao (Medulla Junci), meaning "lamp wick herb," named after the historical use of its loose pith structure as a lamp wick. In Japan, this rush is called igusa (藺草). The species was formally described by Carl Linnaeus in Species Plantarum in 1753.

Botanical Description and Habitat

Juncus effusus is a herbaceous perennial plant with a grass-like appearance, growing around 50–150 cm tall. The stems are smooth cylinders with light pith filling. The yellowish inflorescence appears to emerge from one side of the stem, some distance from the top. It is in flower from June to August, and the species is hermaphrodite, pollinated by wind.

Juncus effusus is nearly cosmopolitan, considered native in Europe, Asia, Africa, North America, and South America; it has also naturalized in Australia, Madagascar, and various oceanic islands. It grows in large clumps at the water's edge along streams and ditches, and is commonly found in humus-rich areas like marshes, ditches, fens, and beaver dams.

Medicinal Part Used and Common Preparations

The medicinal material consists of the dried pith of the individual rushes — the inner, soft material of the stems — which is extracted and dried for use as medicine. The dried stem pith of J. effusus ("Deng Xin Cao") is official in the Pharmacopoeia of the People's Republic of China, and is recommended for the treatment of fidgetiness, insomnia, oliguria, and ulceration in the mouth or on the tongue. The whole herb of J. effusus and its medulla (Medulla Junci, TCM) are also used for the treatment of aphthae, traumatic bleeding, and pharyngitis.

Common preparations encountered in research and traditional practice include:

• Dried stem pith used in water decoctions (tea)
• Ethanolic, methanolic, and aqueous extracts used in laboratory investigations
• The herb first appeared formally in Kaibao Bencao (Materia Medica of the Kaibao Period) around 974 AD.
• A charred form (Deng Xin Tan) used in TCM, with somewhat distinct indications from the raw pith
• Juncus effusus L. var. decipiens (Juncaceae), is a perennial herb widely grown in the marshes of mostly temperate and sub-tropical areas, with its aerial parts used in Japanese folk medicine.

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

Juncus effusus is a well-known TCM herb used as a sedative, anxiolytic, antipyretic, and detumescence agent. It is one of the traditional medicines recorded in the Chinese Pharmacopoeia; the medullae can be used in TCM for the treatment of various diseases such as fidgetiness and insomnia, as well as for its traditional use in China and Japan as an antipyretic and antiphlogistic, and anticancer agent.

In the framework of TCM theory, Deng Xin Cao promotes urination to treat lin zheng (dysuria syndrome) stemming from damp-heat accumulation (with dark, scanty urine). It is also used to address generalized edema and edema connected with nephritis, and it enters the Heart channel to clear Heart heat and sedate fire, addressing insomnia, irritability, and infantile crying at night.

The charred form of Deng Xin Cao clears heat to treat sore throat either internally or topically. In TCM, the herb is classified with the properties of being sweet, bland, and slightly cold, and its functions encompass promoting urination, leaching out dampness and unblocking painful urinary dysfunction, clearing the Heart and directing fire downward, clearing Lung heat, and cooling the Blood.

Junci Medulla is also used in traditional Chinese medicine to promote diuresis for strangury and to clear out heart fire. In Cantonese traditional practice, Juncus effusus is one of the seven ingredients of hui sup tea (去濕茶), a traditional formula for clearing dampness.

Japanese Traditional Use

The aerial part of soft rush, called igusa in Japan, has been used as a folk medicine for antiphlogistic, diuretic, and other medicinal purposes. Further studies have disclosed multifaceted functions of this plant in antifungal, gastrointestinal spasmolytic, anticancer, and anxiolytic activities.

Native American Use (Cherokee)

The Cherokee took a decoction of the plant as an emetic, while an infusion was used to wash babies to strengthen them and prevent lameness.

Middle Eastern and Central Asian Use

In Iran and Afghanistan, the rush is used to weave light, inexpensive mats. It is called halfa (حلفا) and also carries medicinal uses.

European Historical Use

In Europe, this rush was once used to make rushlights by soaking the pith in grease, serving as a cheap alternative to candles. The stem pith's use as a lamp wick gave rise to the plant's Chinese name, Deng Xin Cao ("lamp heart herb"). Traditional European herbalists described the pith as possessing diuretic, sedative, and anti-inflammatory properties, particularly in conditions of urinary difficulty and febrile illness.

Broad Ethnomedical Summary

The pith of the stem has been described as antiphlogistic, depurative, discutient, diuretic, febrifuge, lenitive, lithontriptic, pectoral, and sedative. It has been used in the treatment of sore throats, jaundice, oedema, acute urinary tract infection, and morbid crying of babies. In TCM, J. effusus is used as a sedative, anxiolytic, antipyretic, and to reduce swelling.

3. Key Phytochemical Constituents

Phenanthrenes — The Signature Compound Class

Besides flavonoids, phenanthrenes are the main bioactive constituents of the Juncaceae species. To date, more than one hundred phenanthrenes have been isolated from ten Juncus species. J. effusus is an especially prolific source, with 58 phenanthrene compounds reported from it in previous studies.

Almost one hundred natural phenanthrenes have been isolated from eight Juncaceae species, including mono- and diphenanthrenes, and phenanthrene glucosides. A large number of isolated compounds are substituted with a vinyl group, a substitution characteristic exclusively to Juncaceae species.

The principal identified phenanthrenes from J. effusus include:

• Dehydroeffusol — the most pharmacologically studied compound
• Effusol
• Juncusol
• Dehydrojuncusol
• Effususins A–D (dimeric phenanthrenes)

Eight phenanthrenes have been specifically isolated from the aerial part of Juncus effusus, including 7-carboxy-2-hydroxy-1-methyl-5-vinyl-phenanthrene; 2,7-dihydroxy-1-methyl-5-aldehyde-9,10-dihydrophenanthrene; dehydroeffusol; dehydrojuncusol; effusol; and juncusol.

The richest source of phenanthrenes, as well as the most extensively investigated species, is J. effusus. Several isolated compounds possess different biological activities, including antiproliferative, antimicrobial, anti-inflammatory, antioxidant, spasmolytic, anxiolytic, and antialgal effects.

Other Secondary Metabolites

Previous investigations of secondary metabolites from J. effusus have resulted in the isolation of phenanthrene derivatives, benzocoumarins, triterpenes, flavonoids, phenolic acid derivatives, and steroids.

Deng Xin Cao contains dehydroeffusol, dehydrojuncusol, various carboxyl- and hydroxyl-substituted phenanthrenes, juncosides I–V, oleanolic acid, cycloart-23Z-ene-3β,25-diol, β-sitosterol, β-daucosterol, 5α-spinasterol, 7-oxo-β-sitosterol, the flavonoids luteolin, nobiletin, quercetin, tricin, chrysoeriol, and eriodictyol, along with glycerides, vanillic acid, p-hydroxybenzoic acid, caffeic acid, ferulic acid, emodin, polysaccharides, fatty acids, and trace elements.

Since various Juncus phenanthrenes are substituted with a vinyl group, such compounds are considered important chemotaxonomic markers of the genus.

4. Established Mechanisms of Action

GABA_A Receptor Modulation (Anxiolytic/Sedative Mechanism)

The gamma-amino butyric acid (GABA) type A (GABA_A) receptor represents a crucial target for clinical agents in the treatment of anxiety and insomnia. Using the two-microelectrode voltage clamp technique on recombinant α₁β₂γ₂S GABA_A receptors, effusol and dehydroeffusol were isolated in a bioactivity-guided approach from the pith of Juncus effusus. Both compounds concentration-dependently enhanced GABA-induced chloride currents by a maximum 188 ± 20% (effusol) and 239 ± 18% (dehydroeffusol), independent of the benzodiazepine binding site. This activity on the GABA_A receptor may explain the traditional use of J. effusus as a sedative and anxiolytic agent in Chinese medicine.

Anti-inflammatory Mechanisms

Research results indicate that J. effusus extract exhibited anti-inflammatory activities by suppressing the production of inflammatory mediators in LPS-stimulated RAW 264.7 cells and by attenuating edema in mice. Phenanthrene compounds from the medulla have been shown to inhibit nitric oxide (NO) production in lipopolysaccharide-stimulated macrophages, a well-established in vitro marker for anti-inflammatory activity.

Anticancer Mechanisms (Preclinical)

The active component dehydroeffusol effectively inhibited gastric cancer cell proliferation and tumorigenesis by inducing tumor-suppressive endoplasmic reticulum (ER) stress and by triggering moderate apoptosis. Mechanistic studies revealed that dehydroeffusol selectively activated the intracellular tumor-suppressive stress response by promoting overexpression of the key ER stress marker DNA damage-inducible transcript 3 (DDIT3), through upregulation of activating transcription factor 4 (ATF4).

Antimicrobial and Photosensitizing Mechanisms

Isolation from Juncus effusus of the phenanthrene dehydroeffusol and the dihydrophenanthrene juncusol revealed compounds that display enhanced antimicrobial activities in the presence of light. The antimicrobial activities against methicillin-resistant and -sensitive Staphylococcus aureus and Candida albicans were increased 16- and two-fold, respectively, by irradiation with ultraviolet A (UVA). Photosensitized DNA-binding activities of these compounds were determined; under UVA irradiation, dehydroeffusol strongly inhibited all restriction enzymes that have at least one 5′-TpA sequence in their recognition sites, indicating a sequence-selective, light-dependent DNA-binding mechanism.

OAT Transporter Inhibition

Organic anion transporters 1 (OAT1) and 3 (OAT3) play important roles in the renal elimination of a range of substrate molecules. Little is known about natural products that can modulate OAT1 and OAT3 activities. The medullae of Juncus effusus are often used for the treatment of dysuria in TCM. A bioactivity-guided phytochemical investigation led to the identification of seven new phenanthrenoids along with nine known compounds from the medullae with OAT-inhibitory properties.

Neuroprotective Mechanisms

Pre-administration of dehydroeffusol has been shown to protect against amyloid β1-42-mediated neurodegeneration in the hippocampus by reducing intracellular Zn²⁺ toxicity, which is linked with induced synthesis of metallothioneins. Dehydroeffusol, a unique Juncus effusus phenanthrene, ameliorates neurodegeneration in the dentate granule cell layer, which is most vulnerable to amyloid β1-42 neurotoxicity in the hippocampus.

5. Scientific Evidence by Area of Use

5.1 Anxiety and Sedation

Evidence type: Preclinical (animal behavioral studies); no published human clinical trials identified.

Dehydroeffusol, a phenanthrene isolated from Juncus effusus, possesses characteristic anxiolytic and sedative properties as determined by an array of behavioral tests in mice. In the elevated plus-maze test, dehydroeffusol significantly increased the number of entries into the open arms and the time spent there in a dose-dependent manner, with a minimum effective dose of 2.5 mg/kg. In the hole-board test, it significantly increased head-dips in a dose-dependent manner, with a minimum effective dose of 5 mg/kg. It reduced mouse locomotion in the open-field test with a minimum effective dose of 5 mg/kg. In the rota-rod test, 1–5 mg/kg did not decrease the fall-down time of mice, confirming that dehydroeffusol possesses anxiolytic and sedative properties without affecting general movement coordination.

Effusol and juncusol, two further phenanthrenes isolated from the aerial part, also showed anxiolytic and sedative activities in preclinical models.

The GABA_A receptor modulation demonstrated in vitro provides a plausible mechanistic underpinning for these behavioral effects. However, all evidence in this area is preclinical (rodent models and in vitro electrophysiology); no human randomized controlled trials have been conducted on soft rush extracts for anxiety or insomnia. The evidence base is therefore preliminary and cannot be extrapolated directly to human therapeutic use.

5.2 Anti-inflammatory Effects

Evidence type: In vitro and in vivo animal models; one in vitro cell-based study in an oral health context.

An aqueous extract of Juncus effusus, prepared at 60°C, decreased production of interleukin-8 (IL-8) and CCL20 in oral keratinocytes under LPS stimulation. The study (Wada et al., 2022, BioMed Research International) investigated the effect of a water extract from J. effusus L. on the inhibition of the inflammatory reaction elicited by bacterial infection.

J. effusus has generally been used as an indigenous medicine as a diuretic, antipyretic, and analgesic. The study examined its effects on IL-8 production in Porphyromonas gingivalis LPS-stimulated oral keratinocytes (RT-7 cells) cultured with the water extract at 20- or 100-fold dilution or EGCG (50 μg/mL) and P. gingivalis LPS (1 μg/mL) for 24 hours.

Multiple in vitro studies have demonstrated inhibition of NO production in LPS-activated RAW 264.7 murine macrophage cells by phenanthrene compounds isolated from J. effusus. The total body of anti-inflammatory evidence consists almost entirely of cell-based in vitro studies and rodent models. No human clinical trials specifically targeting inflammatory endpoints have been published for soft rush extracts.

5.3 Anticancer / Antiproliferative Activity

Evidence type: In vitro (cell line studies) and limited in vivo animal data; no human clinical trials.

Dehydroeffusol inhibited the proliferation and migration of SGC-7901 and AGS gastric cancer cell lines in vitro and exhibited significant suppression of SGC-7901 cell-mediated vasculogenic mimicry in vitro and in vivo without substantial acute toxicity. This compound effectively inhibited gastric cell growth and tumorigenicity through inducing tumor-suppressive endoplasmic reticulum (ER) stress responses and concurrently diminishing tumor adaptive ER responses.

The dimeric phenanthrene effususin B possessed pronounced cytotoxic activity against HepG2 (IC₅₀ 12.9 μM), MCF-7 (IC₅₀ 12.5 μM), and SMMC-7721 (IC₅₀ 13.6 μM) cell lines in the CCK-8 assay.

Juncusol and effusol possessed significant antiproliferative activity on HeLa cells (IC₅₀ values of 0.5 μM for juncusol and 2.3 μM for effusol, respectively).

Juncusol was shown to be active against NCI 90 KB (human epidermoid nasopharynx carcinoma) cells with an ED₅₀ of 0.3 μg/mL.

All antiproliferative and anticancer data are from cell-line and animal experiments. There are no human clinical trials. The evidence is preliminary, and the significance for human cancer prevention or treatment is entirely unknown at this stage.

5.4 Antimicrobial Activity

Evidence type: In vitro studies; no human clinical trials.

Dehydroeffusol was proved to be active against methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and MRSA), Bacillus subtilis, and Candida albicans in both normal (dark) and UVA-irradiated conditions. Under UVA irradiation, dehydroeffusol functioned as a DNA-binding photosensitizer.

Juncusol inhibited Bacillus species at all concentrations tested, while Planococcus species were inhibited only at the highest concentration.

The photosensitizing mechanism, in which UVA irradiation markedly amplifies antimicrobial potency, is of particular mechanistic interest but is also a phototoxicity consideration (see Safety section). All data are in vitro.

5.5 Urinary Tract and Diuretic Effects

Evidence type: Traditional use with long pharmacopoeial documentation; no controlled human clinical trials identified.

The dried stem pith of J. effusus is official in the Pharmacopoeia of the People's Republic of China and is recommended for the treatment of fidgetiness, insomnia, oliguria, and ulceration in the mouth or on the tongue. Deng Xin Cao promotes urination to treat dysuria syndrome stemming from damp-heat accumulation (with dark, scanty urine) and also addresses generalized edema and edema connected with nephritis in TCM practice.

The mechanistic plausibility for diuretic effects is supported by the plant's well-documented use across multiple traditional medical systems. However, no randomized controlled trials in humans have evaluated the diuretic efficacy of soft rush preparations by contemporary scientific standards.

5.6 Neuroprotection and Cognitive Effects

Evidence type: Preclinical (rodent) studies only; no human data.

Dehydroeffusol, a unique Juncus effusus phenanthrene, ameliorates neurodegeneration in the dentate granule cell layer, which is most vulnerable to amyloid β1-42 neurotoxicity in the hippocampus. Research has further indicated that the compound may rescue spatial working memory deficits induced by amyloid β25-35 in rodent models. These findings are entirely preclinical, and no clinical implications can be drawn for humans.

5.7 Oral Health and Periodontal Inflammation

Evidence type: In vitro cell-based study (2022).

J. effusus has generally been used as an indigenous medicine such as a diuretic, an antipyretic, and an analgesic in ancient practice. A 2022 study examined the effects of a water extract from J. effusus L. on the inhibition of the inflammatory reaction elicited by bacterial infection and protection of the oral epithelium against chemical irritation. The study demonstrated that the water extract reduced IL-8 and CCL20 production in LPS-stimulated oral keratinocytes, and findings suggested potential utility in formulating ethanol-free oral care products. This remains an early-stage, in vitro finding without clinical validation.

6. Body Systems and Health Areas Associated with Soft Rush

• Urinary/Renal System: Diuretic use, dysuria, oliguria, nephritis-associated edema — documented across TCM, Japanese, and multiple traditional systems.
• Central Nervous System: Sedative, anxiolytic, and antipyretic use — supported by preclinical mechanistic studies involving GABA_A receptor modulation.
• Immune/Inflammatory System: Anti-inflammatory activity demonstrated in vitro via inhibition of NO, IL-8, and CCL20 production in stimulated immune and epithelial cells.
• Gastrointestinal System: Gastrointestinal spasmolytic activity has been reported among the multifaceted functions of this plant.
• Antimicrobial / Skin: Light-dependent antimicrobial activity (MRSA, Candida albicans) studied in vitro; phototoxic potential noted.
• Oncology (Preclinical): Antiproliferative activity demonstrated against multiple human cancer cell lines in vitro.
• Oral/Mucosal Health: Investigated in vitro for periodontal inflammation and mucosal protection.
• Cardiovascular/Hematological: The species has gained attention as a source of phenanthrenes, phenolic compounds, glycerides, flavonoids, and cycloartane triterpenes; it has been shown to be active in antioxidant, anti-inflammatory, antialgal, and antibacterial investigations.

7. Dosage Forms and Dosages Reported in Studies

Traditional/Pharmacopoeial Dosages

The Pharmacopoeia of the People's Republic of China lists the dried stem pith (Deng Xin Cao) as official, though specific pharmacopoeial dosage ranges are not reproduced in the available secondary sources reviewed here. TCM practitioners typically prescribe Deng Xin Cao as a decoction of the dried stem pith, often as one component in a multi-herb formula.

Doses Used in Preclinical Studies

In rodent behavioral anxiety models, dehydroeffusol showed a minimum effective dose of 2.5 mg/kg in the elevated plus-maze test, 5 mg/kg in the hole-board test, and 5 mg/kg in the open-field locomotion test.

In a preliminary pharmacokinetic study, 100 mg/kg of Juncus effusus extract did not cause any obvious toxic response in mice or rats.

In the oral keratinocyte in vitro study, the J. effusus water extract was applied at 20- or 100-fold dilutions alongside P. gingivalis LPS (1 μg/mL) for 24 hours.

It should be noted that no dose-ranging or dose-finding human clinical trials have been published for soft rush. Preclinical doses expressed in mg/kg cannot be directly converted to human therapeutic doses without pharmacokinetic and safety data from human studies.

8. Safety Considerations and Drug Interactions

General Acute Toxicity

In a preliminary animal study, 100 mg/kg of Juncus effusus extract did not cause any obvious toxic response in mice or rats. While this suggests a reasonable acute safety margin in animals, formal human toxicology studies have not been published.

Photosensitizing / Phototoxic Properties

Dehydroeffusol and juncusol from Juncus effusus display markedly enhanced antimicrobial activities under UVA light, with a 16-fold increase in activity against Staphylococcus aureus and a two-fold increase against Candida albicans under UVA irradiation. The same photosensitizing property that makes these compounds potentially antimicrobial under light exposure raises the question of phototoxic risk, as structurally related compounds known to bind DNA under UV irradiation are associated with phototoxic reactions in humans. This has not been formally characterized in human subjects.

Herb–Drug Interactions: Organic Anion Transporter (OAT) Inhibition

An in vitro study showed that a Juncus effusus extract was a strong inhibitor of OAT3 with an IC₅₀ value of 1.21 μg/mL, and also slightly inhibited OAT1. Although 100 mg/kg of the extract did not cause obvious toxic response in animals, both oral and intravenous co-administration of Juncus effusus markedly increased the AUC₀–t of furosemide in rats. Therefore, consideration must be given to the potential clinical interaction of Juncus effusus with drug substrates of OATs.

OAT1 and OAT3 play important roles in the renal elimination of a range of substrate molecules. The medullae of Juncus effusus are often used for the treatment of dysuria in TCM, and a bioactivity-guided investigation led to the identification of dihydrophenanthrenoid compounds that inhibit these transporters in vitro.

This is a noteworthy and clinically relevant finding: drugs renally eliminated via OAT1 and OAT3 — including furosemide (a loop diuretic), methotrexate, and certain antiviral and antibiotic agents — could potentially have altered pharmacokinetics when co-administered with J. effusus preparations. The only in vivo evidence available is from rat models; human clinical data are absent.

GABA_A Receptor-Mediated CNS Effects and Potential Additive Interactions

Both effusol and dehydroeffusol concentration-dependently enhanced GABA-induced chloride currents via the GABA_A receptor, independent of the benzodiazepine binding site. This activity may explain the traditional use of J. effusus as a sedative and anxiolytic agent. Because these compounds act as positive modulators of GABA_A receptors, the theoretical possibility of additive or potentiated CNS depression in combination with benzodiazepines, barbiturates, alcohol, or other GABAergic agents is mechanistically plausible, though this has not been studied in humans.

Potential Caution for Edible Use

Young shoots of Juncus effusus have been noted as edible when raw, but some caution is advised regarding toxicity. The specific nature of this caution has not been elaborated upon in the peer-reviewed sources reviewed.

Absence of Formal Clinical Pharmacovigilance Data

No systematic reviews, case reports, or post-marketing surveillance data on adverse effects in humans from oral consumption of standardized soft rush preparations were identified in the peer-reviewed literature. The plant's long history of use in official pharmacopoeia in China implies an acceptable traditional safety profile when used in conventional decoction form, but rigorous clinical safety data do not exist.

9. Summary of Evidence Strength

The table below summarizes the current state of evidence for the main areas of use:

• Sedative / Anxiolytic: Moderate preclinical evidence (rodent behavioral studies, in vitro GABA_A receptor data); mechanism is well-characterized; no human clinical data.
• Anti-inflammatory: Preliminary in vitro and animal data; multiple cell-line studies; no human clinical trials.
• Diuretic / Urinary: Extensive traditional use across multiple pharmacopoeias; no modern human clinical trials.
• Antimicrobial: In vitro only; photosensitizer-dependent mechanism; no clinical application data.
• Antiproliferative / Anticancer: Multiple cell-line studies; some limited in vivo rodent data; entirely preclinical.
• Neuroprotection: Rodent models only; no human data.
• Oral Health: Single in vitro study; early-stage, no clinical validation.

Overall, the scientific evidence base for Juncus effusus as a dietary supplement or therapeutic agent is primarily preclinical. The chemistry is richly documented, mechanisms of action have been proposed and partially validated in vitro and in animal models, and the plant has a long pharmacopoeial history. However, rigorous human clinical trials are absent for all indications. Claims about clinical efficacy in humans cannot be substantiated by the current evidence.

References

• Liao YJ et al. Anxiolytic and sedative effects of dehydroeffusol from Juncus effusus in mice. Planta Med. 2011;77:416–420. PubMed
• Wang YG et al. Phenanthrenes from Juncus effusus with anxiolytic and sedative activities. Nat Prod Res. 2012;26(13):1234–1239. PubMed
• Singhuber J et al. GABA(A) receptor modulators from the Chinese herbal drug Junci Medulla — the pith of Juncus effusus. Planta Med. 2012;78:455–458. PubMed
• Dehydroeffusol inhibits gastric cancer cell growth and tumorigenicity by selectively inducing tumor-suppressive endoplasmic reticulum stress and moderate apoptosis. Biochem Pharmacol. 2016. ScienceDirect
• Wada A et al. Anti-Inflammatory and Protective Effects of Juncus effusus L. Water Extract on Oral Keratinocytes. Biomed Res Int. 2022;2022:9770899. PMC
• Lu H et al. Interactions of 172 plant extracts with human organic anion transporter 1 (SLC22A6) and 3 (SLC22A8): a study on herb-drug interactions. PeerJ. 2017;5:e3333. PMC
• Li X et al. Dihydrophenanthrenes from Juncus effusus as Inhibitors of OAT1 and OAT3. J Nat Prod. 2019. PubMed
• Phenanthrenes from Juncus compressus Jacq. with Promising Antiproliferative and Anti-HSV-2 Activities. Molecules. 2018;23(8):2085. PMC
• Antiproliferative Phenanthrenes from Juncus tenuis: Isolation and Diversity-Oriented Semisynthetic Modification. PMC 2020
• Kovács A et al. Family Juncaceae: promising source of biologically active natural phenanthrenes. Phytochem Rev. 2018. Springer
• Moerman DE, Phytochemistry of Cherokee Aromatic Medicinal Plants. PMC 2019
• In vitro anti-inflammatory effects of edible igusa soft rush. Food Science and Technology Research. 2016;22(3):395. J-Stage
• Hanawa F et al. Antimicrobial DNA-binding photosensitizers from the common rush, Juncus effusus. Photochem Photobiol. 2002;76(1):51–56. ResearchGate
• Dehydroeffusol prevents amyloid β1-42-mediated hippocampal neurodegeneration via reducing intracellular Zn²⁺ toxicity. Mol Neurobiol. 2021. Springer
• Deng Xin Cao (Medulla Junci): Uses, Benefits, Side Effects, Warnings. TCM Library
• Juncus effusus. Wikipedia
• Juncus effusus — Soft Rush, Common Rush. Plants for a Future (PFAF) Database
• Bús Csaba. Phytochemical investigation of Juncus species. University of Szeged, Faculty of Pharmacy. Doctoral Dissertation.
• Cytotoxic and Anti-inflammatory Constituents from Juncus effusus. J Mex Chem Soc. 2016;60(2). SciELO
• Crude Plant Extracts and Their Anti-Inflammatory Potential in Oral Inflammatory Cell Models: A Systematic Review of In Vitro Studies. PMC 2025